Floatz logo

Rimiducid

X-linked Lymphoproliferative Disease

Baylor College of MedicineSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the X-linked Lymphoproliferative Disease cohort.

Asset / SponsorPhaseRating
Thiotepa
University of Florida
Phase 2BB
Cytosin-Arabinosid
Baylor College of Medicine
Phase 2B
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
Phase 2B
Evomela
Washington University School of Medicine
Phase 2CCC
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Washington University School of Medicine
Phase 2CCC

View all 17 →

Same molecule, other indications

Rimiducid is also rated in:

myelodysplastic syndromeDormant
CCC
Indicative ·
51 / 100
View asset →
inborn error of immunityDormant
CCC
Indicative ·
50 / 100
View asset →
myeloproliferative neoplasmDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →